PDGFRA and neoplasm: In our study, we deployed a customized targeted panel (Archer® LiquidPlexTM) comprising 29 cancer and/or GIST-associated genes, emphasizing the utility of a larger sequencing footprint in picking up clinically relevant mutations beyond KIT and PDGFRA. Similar to a previous report (18), the sensitivity of our assay depends on tumor size, and is most applicable in the setting of progressive disease and TKI resistance.